BioMarin Submits CTA for BMN-190 for Batten Disease
SAN RAFAEL, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. for BMN-190, a recombinant human tripeptidyl peptidase 1 (rhTPP1) for the treatment of patients with neuronal ceroid lipofuscinosis type 2 (NCL-2), a form of Batten disease. The company expects to start enrolling patients in a Phase 1/2 trial in mid-2013.
Dr. Scott Kachlany of the New Jersey Dental School at UMDNJ is featured in myCentralJersey.com -- New drug in development shows promise for treatment of leukemia, lymphoma and 80 autoimmune diseases
For Immediate Release January 25, 2013 Contact: Dale R. Heffler (908) 731-6605 email@example.com
Foundation Venture Capital Group Invests In Start-Up Working to Reduce Side Effects of Parkinson’s Treatment
New Brunswick, NJ—Parkinson’s disease affects one million people in the United States and seven million worldwide. While L-Dopa is effective in treating the disease symptoms, the vast majority of patients taking it chronically eventually develop L-Dopa Induced Dyskinesia (LID), abnormal involuntary movements that can be disabling.
A new company, MentiNova, Inc., is exploring an oral medication that could reduce these uncontrollable, often chaotic movements in patients being treated with L-Dopa. Foundation Venture Capital Group (FVCG), an affiliate of New Jersey Health Foundation, has committed up to $500,000 to advance this research and development.
Full Press Release
A Healthy Venture in New Jersey
New Jersey Health Foundation and the University of Medicine and Dentistry of New Jersey collaborate on new venture model to commercialise university IPs.
Author: Tim Lafferty, Managing Director, Global University Venturing
New Jersey Health Foundation and the University of Medicine and Dentistry of New Jersey (UMDNJ) have developed a rare venture model to foster the commercialisation of university intellectual property (IP).